Nucelion Therapeutics and Pandorum Technologies have started a ₹17 crore project to develop gene therapy for eye conditions. With ₹8 crore supported by the government's PRIP scheme, the deal highlights growing institutional interest in India’s high-tech regenerative medicine sector.
Hyderabad-based Nucelion Therapeutics and Bengaluru-based Pandorum Technologies have formed a strategic partnership to develop treatments for two ophthalmology conditions: advanced keratopathy and wet age-related macular degeneration (wet AMD). The collaboration, valued at ₹17 crore, aims to bridge the gap between laboratory research and clinical trials using advanced regenerative medicine technology.
The project is supported by the federal government under the Promotion of Research and Innovation in Pharma Medtech (PRIP) scheme, which is providing ₹8 crore in funding. This support reflects a broader government effort to move the Indian pharmaceutical sector beyond generic manufacturing toward higher-value, innovation-led drug development.
Combining Manufacturing and Research
The partnership divides the workload based on each company's specialized expertise. Pandorum Technologies provides its proprietary regenerative medicine platform, specifically using designer exosomes, which are microscopic particles that facilitate cellular communication. Nucelion Therapeutics, operating as a contract development and manufacturing organization (CDMO), is responsible for process development and ensuring the production meets Good Manufacturing Practice (GMP) standards. These standards are mandatory for any therapeutic material used in human clinical trials.
For investors and industry observers, this collaboration is a case study in the capital-intensive nature of the biotech sector in India. Developing gene therapies and regenerative medicines typically requires significant investment before a product can reach the market. The success of this project will depend on the effectiveness of the underlying technology and the ability of the companies to navigate complex clinical trial processes.
Risks and Market Context
While government funding provides a financial buffer, the sector carries inherent risks. Clinical trials for ophthalmology and gene therapy are often lengthy, and there is a high probability of failure at various stages of testing. Even if the science is proven, the regulatory hurdles for getting approval to market these treatments in India and international markets are substantial.
Investors tracking this space often watch for milestones like the completion of pre-clinical studies, successful human trial phases, and regulatory filings with organizations like the Central Drugs Standard Control Organisation (CDSCO). Because these firms are in the specialized biotech space rather than traditional pharma, their performance is closely tied to their ability to secure continued funding and pass rigid scientific validation. The progress of the PRIP-funded projects will be a key indicator of whether indigenous manufacturing can successfully scale for complex biological therapies in the coming years.